FDG-PET/CT Avid Uptake of a Biopsy-Proven Aggressive Melanotic Schwannoma of the S2 Spinal Nerve Root

Overview

Journal World J Nucl Med

Publisher Thieme

Specialty Nuclear Medicine

Date 2025 Feb 17

PMID 39959154

Authors

Mohammed A Azab

Hamid Abdelmaaboud Mostafa

Oday Atallah

Affiliations

Soon will be listed here.

Abstract

Malignant melanotic nerve sheath tumors (MMNSTs), also known as a melanocytic schwannoma (MS), are a rare type of peripheral nerve sheath tumors including Schwann cells with melanocytic differentiation. Only a few cases of spinal MMNST have been reported in literature. Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ( F-FDG-PET/CT) could be used to detect these lesions. A 70-year-old man with a 6-month history of backache was admitted to our hospital. PET/CT showed a paravertebral soft tissue mass along the spinal nerve at the S2 level with strong FDG uptake, and a nodule with increased FDG uptake in the right lobe of the left liver. A CT-guided biopsy of the S2 lesion was performed. The final diagnosis was spinal MS with hepatic metastasis. The patient received stereotactic body radiation therapy. Herein, we report the PET/CT findings of a case of MS with hepatic metastasis. FDG-PET/CT is helpful in the differential diagnosis of benign and malignant lesions although nonspecific.

References

Beaulieu S, Rubin B, Djang D, Conrad E, Turcotte E, Eary J . Positron emission tomography of schwannomas: emphasizing its potential in preoperative planning. AJR Am J Roentgenol. 2004; 182(4):971-4. DOI: 10.2214/ajr.182.4.1820971. View

Shen X, Wang W, Luo Z . 18F-FDG PET/CT imaging for aggressive melanotic schwannoma of the L3 spinal root: A case report. Medicine (Baltimore). 2021; 100(8):e24803. PMC: 7909145. DOI: 10.1097/MD.0000000000024803. View

Haleem S, Mahmoud M, Kainth G, Botchu R, Hassan M . 18F-FDG PET/CT scan standardised uptake value (SUV) score for diagnosis, staging and monitoring malignancy in spinal melanotic schwannoma. J Surg Case Rep. 2022; 2022(12):rjac524. PMC: 9731614. DOI: 10.1093/jscr/rjac524. View

Santaguida C, Sabbagh A, Guiot M, Del Maestro R . Aggressive intramedullary melanotic schwannoma: case report. Neurosurgery. 2004; 55(6):1430. DOI: 10.1227/01.neu.0000143617.25417.68. View

Salamon J, Papp L, Toth Z, Laqmani A, Apostolova I, Adam G . Nerve Sheath Tumors in Neurofibromatosis Type 1: Assessment of Whole-Body Metabolic Tumor Burden Using F-18-FDG PET/CT. PLoS One. 2015; 10(12):e0143305. PMC: 4666520. DOI: 10.1371/journal.pone.0143305. View

Knight S, Delbeke D, Stewart J, Sandler M . Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest. 1996; 109(4):982-8. DOI: 10.1378/chest.109.4.982. View

Chirindel A, Chaudhry M, Blakeley J, Wahl R . 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization. J Nucl Med. 2015; 56(3):379-85. DOI: 10.2967/jnumed.114.142372. View

Lieber B, Han B, Allen J, Fatterpekar G, Agarwal N, Kazemi N . Utility of positron emission tomography in schwannomatosis. J Clin Neurosci. 2016; 30:138-140. DOI: 10.1016/j.jocn.2016.01.027. View

Warbey V, Ferner R, Dunn J, Calonje E, ODoherty M . [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging. 2009; 36(5):751-7. DOI: 10.1007/s00259-008-1038-0. View

10.

Ferner R, Golding J, Smith M, Calonje E, Jan W, Sanjayanathan V . [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2007; 19(2):390-4. DOI: 10.1093/annonc/mdm450. View

11.

Ferner R, Lucas J, ODoherty M, Hughes R, Smith M, Cronin B . Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry. 2000; 68(3):353-7. PMC: 1736834. DOI: 10.1136/jnnp.68.3.353. View

12.

Solomou G, Silva A, Wong A, Pohl U, Tzerakis N . Extramedullary malignant melanotic schwannoma of the spine: Case report and an up to date systematic review of the literature. Ann Med Surg (Lond). 2020; 59:217-223. PMC: 7559563. DOI: 10.1016/j.amsu.2020.10.003. View

13.

Derlin T, Tornquist K, Munster S, Apostolova I, Hagel C, Friedrich R . Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med. 2012; 38(1):e19-25. DOI: 10.1097/RLU.0b013e318266ce84. View

14.

Salamon J, Veldhoen S, Apostolova I, Bannas P, Yamamura J, Herrmann J . 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off. Eur Radiol. 2013; 24(2):405-12. DOI: 10.1007/s00330-013-3020-x. View

15.

Mouchaty H, Conti R, Buccoliero A, Conti P . Intramedullary melanotic schwannoma of the conus medullaris: a case report. Spinal Cord. 2008; 46(10):703-6. DOI: 10.1038/sc.2008.9. View

16.

Shah N, Sibtain A, Saunders M, Townsend E, Wong W . High FDG uptake in a schwannoma: a PET study. J Comput Assist Tomogr. 2000; 24(1):55-6. DOI: 10.1097/00004728-200001000-00011. View

17.

Brahmi M, Thiesse P, Ranchere D, Mognetti T, Pinson S, Renard C . Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients. PLoS One. 2015; 10(10):e0138386. PMC: 4596851. DOI: 10.1371/journal.pone.0138386. View

18.

Acciarri N, Padovani R, Riccioni L . Intramedullary melanotic schwannoma. Report of a case and review of the literature. Br J Neurosurg. 1999; 13(3):322-5. DOI: 10.1080/02688699943772. View

19.

Wassef M, Lot G, Catala M, Moussalam M, Caruel N, Mikol J . Spinal melanotic schwannoma: a tumour with poor prognosis. Histopathology. 1999; 35(6):558-66. DOI: 10.1046/j.1365-2559.1999.00786.x. View

20.

Torres-Mora J, Dry S, Li X, Binder S, Amin M, Folpe A . Malignant melanotic schwannian tumor: a clinicopathologic, immunohistochemical, and gene expression profiling study of 40 cases, with a proposal for the reclassification of "melanotic schwannoma". Am J Surg Pathol. 2013; 38(1):94-105. DOI: 10.1097/PAS.0b013e3182a0a150. View